FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...

Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in ...